JPRN-jRCT2080221670未知1 期
Phase I/II trial of YHI-1003 plus Capecitabine in Patients with Refractory Advanced Colorectal Cancer
试验速览
- 阶段
- 1 期
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1)Patients with recurrent or metastatic colorectal cancer
- •(2)Patients must have failed available therapy for the treatment of advanced colorectal cancer.
- •(3)No prior exposure to capecitabine and S-1
- •(4)ECOG performance status (PS) :0-1
排除标准
- •(1)Patients with uncontrolled intercurrent illness
- •(2)Female patients who are pregnant or lactating
- •(3)Patients with known central nervous system CNS metastases
研究者
相似试验
未知
1 期
Phase I trial of YHI-1003 plus Bortezomib and DexamethasoneRelapsed Multiple Myeloma previously treated with BortezomibJPRN-jRCT2080221706Yakult Honsha Co., Ltd.18
未知
2 期
Phase II trial of YHI-1003JPRN-jRCT2080222238Yakult Honsha Co., Ltd.96
已完成
不适用
Phase I/II trial of capecitabine plus irinotecan for metastatic breast cancer patient who pretreated with anthracycline and taxane agentsmetastatic breast cancerJPRN-UMIN000001531ational cancer center hospital30
未知
1 期
Phase I trial of YHI-1003relapsed or refractory neuroblastomaJPRN-jRCT2080222084Yakult Honsha Co., Ltd.18
已完成
1 期
Capecitabine and erlotinib in advanced lung cancerCancerISRCTN18199864Royal Marsden NHS Foundation Trust40